Background
==========

It has been reported that anakinra, an anti-IL-1R antagonist, may be a safe alternative during pregnancy in patients with various autoinflammatory syndromes (1,2).

Objectives
==========

To assess the safety and efficacy of anakinra in pregnant FMF patients.

Methods
=======

Five FMF patients, treated with anakinra during pregnancy were monitored for side effects, fetal and maternal outcomes.

Results
=======

We present five FMF cases treated with Anakinra during pregnancy due to severe protracted febrile myalgia in 3, thrombocytopenia in 1 and amyloidosis in 1. One of these cases is among the 5 patients that have been previously reported (1). Throughout pregnancy no anakinra-related adverse event was observed in any of the patients. During the postpartum period one patient had an incision-site infection and the baby of the patient with thrombocytopenia also developed low platelet count which resolved with IVIG therapy. Otherwise all patients delivered normal babies. One of the patients is still pregnant and expecting twins. All of the patients, except one with colchicine intolerance continued with daily prophylactic colchicine treatment. Anakinra was terminated shortly after birth with success in all. Pregnancy-related features are listed in Table [1](#T1){ref-type="table"}.

###### 

pregnancy-related features

  Case   Maternal Age   Anakinra Relation to pregnancy                         USGs     Weeks at delivery or currrent gestational age   Gender of the baby/fetus   Mode of the delivery   1^st^minute APGAR   Follow-up duration after birth (months)   Complications after birth
  ------ -------------- ------------------------------------------------------ -------- ----------------------------------------------- -------------------------- ---------------------- ------------------- ----------------------------------------- -----------------------------------------------------------------------------------------------------------
  1      33             started at 21st GW and used continiously until birth   normal   Birth at 36th GW                                boy                        C/S                    8                   32                                        No
                                                                                                                                                                                                                                                        
  2      28             started at 12th GW and used until birth                normal   Birth at 40th GW                                girl                       vaginal                10                  20                                        No
                                                                                                                                                                                                                                                        
  3      31             started at 12th GW and used until birth                normal   Birth at 38th GW                                boy                        C/S                    6                   2                                         Methicillin-Sensitive Staphylococcus Aureus incision-site infection (treated with Tygecycline) in mother
                                                                                                                                                                                                                                                        
  4      24             started at 15th GW and used until birth                normal   Birth at 38th GW                                boy                        Vaginal                8                   2                                         Low thrombocyte count in the baby at birth (23,000/mm3); resolved after 3 infusions of IVIG (269,000/mm3)
                                                                                                                                                                                                                                                        
  5      33             started at 16th GW, still using                        normal   At 20th GW                                      Expecting 2 girls                                                                                               

Conclusions
===========

Anakinra promises to be a safe alternative in pregnant FMF patients who are unresponsive or intolerant to colchicine. It can be administered transiently only during pregnancy and stopped after delivery.
